南财智讯10月24日电，迈克生物公告，2025年前三季度公司实现营业收入16.08亿元，同比下降 17.44%；归属于上市公司股东的净利润0.37亿元，同比下降86.81%。基本每股收益0.0606元，同比下降 86.93%。 ...

迈克生物股份有限公司 证券代码：300463 证券简称：迈克生物 公告编号：2025-100 关于 2025 年第三季度计提信用及资产减值准备的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或者重大遗漏。 迈克生物股份有限公司（以下简称"公司"）根据《企业会计准则》《深圳证券交易所上市 公司自律监管指引第2号——创业板上市公司规范运作》中关于计提资产减值准备的相关规定， 基于谨慎性原则，为真实反映公司的财务状况、资产价值及经营情况，对截至2025年9月30日 合并报表范围内可能发生信用及资产减值的有关资产计提信用及资产减值准备。根据相关规定， 本次计提减值准备无需提交公司董事会审议，现将2025 年第三季度计提资产减值准备的具体 情况公告如下： 一、本次计提信用及资产减值准备的范围及金额 公司 2025 年第三季度对相关资产计提信用和资产减值准备 2,064.95 万元。具体如下表： 二、本次计提信用及资产减值准备的确认标准和计提方法 （一）应收款项预期信用损失的确认标准及计提方法 第 1 页 共 5 页 单位：万元 资产类别 2025 年第三季度 计提金额 2025 ...

迈克生物股份有限公司 董事会 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或者重大遗漏。 2025 年 10 月 24 日迈克生物股份有限公司（以下简称"公司"）召开第六届董事会第七次 会议，审议通过了《关于公司 2025 年第三季度报告的议案》。 为使广大投资者全面了解公司的经营、财务状况，公司《2025 年第三季度报告》于 2025 年 10 月 25 日在中国证监会指定的创业板信息披露网站巨潮资讯网（http://www.cninfo.com.cn） 上披露，敬请广大投资者查阅。 特此公告。 证券代码：300463 证券简称：迈克生物 公告编号：2025-097 迈克生物股份有限公司 关于披露《2025 年第三季度报告》的提示性公告 二〇二五年十月二十五日 第 1 页 共 1 页 ...

本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性陈 述或者重大遗漏。 迈克生物股份有限公司 第六届董事会第七次会议决议公告 证券代码：300463 证券简称：迈克生物 公告编号：2025-098 一、董事会会议召开情况 1、迈克生物股份有限公司（以下简称"公司"）第六届董事会第七次会议通知于 2025 年 10 月 14 日以邮件、短信的方式向全体董事发出并送达。 二、董事会会议审议情况 经与会董事认真审议，本次会议以书面表决方式通过以下议案： （一）审议通过《关于公司 2025 年第三季度报告的议案》 公司 2025 年第三季度报告全文的编制程序符合法律、法规和中国证监会的有关规定，报 告内容真实、准确、完整地反映了公司的实际情况，不存在任何虚假记载、误导性陈述或者重 大遗漏。 本议案已经第六届董事会审计委员会第五次会议审议通过后一致同意提交董事会审议。 表决结果：9 票赞成，0 票反对，0 票弃权，0 票回避 三、备查文件 2、本次会议于 2025 年 10 月 24 日在公司会议室以现场和通讯相结合的方式召开。 3、本次会议应出席会议的董事 9 人，实际出席会议的董事 9 人。 ...

Financial Performance - The company's revenue for Q3 2025 was ¥532,849,978.83, a decrease of 20.32% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥3,060,863.16, down 96.16% year-on-year, while the net profit excluding non-recurring items was ¥1,250,879.71, a decline of 98.66%[5]. - Total operating revenue decreased to ¥1,607,884,075.22 from ¥1,947,615,476.64, representing a decline of approximately 17.4% year-over-year[23]. - Net profit for the period was ¥43,024,083.77, down from ¥283,096,995.04, indicating a decline of approximately 84.8% year-over-year[24]. - Basic earnings per share were ¥0.0050, down 96.15% compared to the same period last year[5]. - Basic earnings per share for the period was CNY 0.0606, down from CNY 0.4635 in the previous period[25]. - Diluted earnings per share for the period was CNY 0.0606, compared to CNY 0.4594 in the previous period[25]. Cash Flow and Investments - The net cash flow from operating activities for the year-to-date was ¥310,378,651.88, representing a decrease of 37.04% compared to the previous year[11]. - Investment cash flow for the year-to-date was -¥484,482,792.58, a decrease of 10.32% year-on-year, attributed to reduced investment in the Tianfu International Biological City IVD Industrial Park project[11]. - Cash inflow from financing activities was CNY 830,309,635.83, an increase of 43% from CNY 580,793,037.56 in the previous period[27]. - Net cash flow from investing activities was -CNY 484,482,792.58, slightly improved from -CNY 540,240,818.26 in the previous period[27]. - Total cash outflow from operating activities was CNY 1,681,369,859.76, down from CNY 1,811,099,189.49 in the previous period[27]. Assets and Liabilities - Total assets at the end of the reporting period were ¥7,988,985,705.04, showing a slight increase of 0.16% from the end of the previous year[5]. - Total liabilities rose to ¥1,609,600,676.96 from ¥1,552,644,190.08, an increase of about 3.7% year-over-year[21]. - The company's equity attributable to shareholders decreased to ¥6,326,115,358.60 from ¥6,369,056,728.78, a decline of approximately 0.7%[21]. - Cash and cash equivalents at the end of the period amount to RMB 674,786,812.33, slightly increasing from RMB 671,453,066.24 at the beginning[19]. - Cash and cash equivalents decreased to ¥3,412,441,963.83 from ¥3,639,623,036.94, a drop of about 6.2%[20]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 33,893[13]. - The largest shareholder, Tang Yong, holds 11.26% of shares, totaling 68,062,301 shares, with 51,046,726 shares under lock-up[13]. - The company has a total of 120,621,001 restricted shares at the beginning of the period, with 7,762,787 shares released and 8,250 shares added, resulting in 112,866,464 restricted shares at the end[16]. - The company plans to reduce its registered capital by 7,802,966 shares, changing the total shares from 612,469,590 to 604,666,624[17]. - The company has transferred 51% equity of its subsidiary, Shandong Mike Biotechnology Co., Ltd., for a transaction price of RMB 17,412,879[17]. Operational Metrics - Accounts receivable decreased by 18.16% to ¥1,279,303,091.22 due to improved collection management[9]. - Accounts receivable decreased from RMB 1,563,178,437.53 to RMB 1,279,303,091.22 during the reporting period[19]. - Inventory increased from RMB 901,575,563.10 to RMB 931,047,217.76[19]. - The gross profit margin was negatively impacted by a 31.48% increase in taxes and surcharges due to increased deductible VAT[10]. - The company experienced a 223.26% rise in non-operating expenses, totaling ¥28,031,587.08, primarily due to tax payments and equipment write-offs[10]. Research and Development - Research and development expenses were ¥206,458,830.00, compared to ¥223,099,816.06 in the previous period, reflecting a decrease of about 7.4%[24]. Audit Status - The company’s financial report for the third quarter was not audited[29].

Core Viewpoint - On October 22, 2023, Maike Bio experienced a slight increase in stock price by 0.34%, with a trading volume of 52.52 million yuan. The company reported a net financing outflow of 374,200 yuan for the day, indicating a low financing balance relative to its market value [1] Financing and Margin Trading - On October 22, Maike Bio had a financing buy-in of 6.50 million yuan and a financing repayment of 6.88 million yuan, resulting in a net financing buy-in of -374,200 yuan. The total financing and margin trading balance reached 325 million yuan [1] - The current financing balance of 323 million yuan accounts for 4.58% of the circulating market value, which is below the 30th percentile level over the past year, indicating a low position [1] - In terms of margin trading, Maike Bio repaid 1,900 shares and sold 100 shares on October 22, with a selling amount of 1,167 yuan. The remaining margin balance is 1.57 million yuan, which exceeds the 90th percentile level over the past year, indicating a high position [1] Company Overview - Maike Bio, established on October 20, 1994, and listed on May 28, 2015, is located in Chengdu, Sichuan Province. The company focuses on the research, production, sales, and related services of in vitro diagnostic products [1] - The main business revenue composition includes 81.11% from self-developed products, 17.96% from agency products, and 0.93% from other supplementary sources [1] Financial Performance - As of June 30, 2023, Maike Bio reported a total of 35,000 shareholders, a decrease of 0.18% from the previous period. The average circulating shares per person increased by 0.25% to 14,031 shares [2] - For the first half of 2025, Maike Bio achieved an operating income of 1.075 billion yuan, a year-on-year decrease of 15.94%. The net profit attributable to the parent company was 34.04 million yuan, down 83.12% year-on-year [2] Dividend Distribution - Since its A-share listing, Maike Bio has distributed a total of 1.278 billion yuan in dividends, with 370 million yuan distributed over the past three years [3] Institutional Holdings - As of June 30, 2023, Hong Kong Central Clearing Limited was the eighth largest circulating shareholder of Maike Bio, holding 5.1207 million shares, a decrease of 8.7749 million shares compared to the previous period [3]

Core Viewpoint - The company, Maike Bio (300463), has successfully developed and produced its fully automated biochemical analysis systems, which have been recognized in the Sichuan Province's innovation medical device integration application pilot project [1] Group 1: Company Innovations - The fully automated biochemical analysis systems are entirely self-produced by the company [1] - The C2000/C1000 fully automated biochemical analysis system represents a breakthrough in independent innovation technology in the biochemical testing field [1] - The innovation effectively addresses the technical pain points of frequent validation in medical laboratory biochemical analysis [1]

Core Viewpoint - The IVD industry chain is experiencing intensified competition in the A-share market, driven by national policies, with the company focusing on the research, production, sales, and related services of in vitro diagnostic products [1] Company Summary - The company has over 30 years of experience in the development of in vitro diagnostic devices, reagents, calibrators, and quality control products, establishing a systematic professional capability [1] - The company has completed the layout of the entire industry chain, from biological raw materials to medical laboratory products and specialized services [1] - The company is entering a development phase focused on building smart laboratories through automation and intelligent products [1] - The company aims to continuously enhance its domestic and international marketing network to increase market share and brand influence [1] Industry Summary - There are over 70 companies listed in the A-share market within the IVD industry chain, indicating a competitive landscape [1]

Core Viewpoint - The company, Maike Bio (300463.SZ), is currently not involved in the development of mass spectrometers or spectrometers, focusing instead on a self-research-driven model complemented by collaborative innovation [1] Group 1: Research and Development Strategy - The company employs a research and development model centered on self-innovation, supplemented by collaborative efforts [1] - It has established a comprehensive technical research and development framework that includes three main areas: technology research, reagent development, and instrument development [1] - The research covers key technical fields such as biochemistry, immunology, hematology, urinalysis, molecular biology, pathology, and IVD raw materials [1] Group 2: Collaboration and Innovation Network - The company has formed partnerships with medical institutions, research institutes, and industry partners to create a multi-layered innovation network [1] - It promotes technological breakthroughs and product transformation through a combination of internal laboratories and external joint research [1] - The approach allows for horizontal coverage across various technological platforms and application scenarios [1]

Core Viewpoint - The company, Maike Bio (300463.SZ), has received a medical device registration certificate from the Sichuan Provincial Drug Administration for its new product, the Glial Fibrillary Acidic Protein Assay Kit, which is intended for auxiliary diagnosis of central nervous system diseases [1] Group 1: Product Registration and Purpose - The Glial Fibrillary Acidic Protein Assay Kit is a new reagent product under the company's direct chemiluminescence platform, used in conjunction with the company's fully automated chemiluminescence immunoassay analyzers (i6000, i3000, i1000, and i800 series) [1] - The company has obtained a total of 138 product registration certificates for reagent products under the direct chemiluminescence platform, covering various disease detections including thyroid function, infectious diseases, myocardial, tumor markers, anemia, inflammation, autoimmune diseases, reproductive hormones, and bone metabolism [1] - The blood cell analyzer quality control products and calibration products are newly added to the company's blood cell platform, ensuring the accuracy of clinical blood cell analysis results [1] Group 2: Registration Details - The blood cell analyzer quality control product has a registration number of 20252400168, valid from September 24, 2025, to September 23, 2030, and is used for quality control of blood cell analysis projects [2] - The Glial Fibrillary Acidic Protein Assay Kit has a registration number of 20252400179, valid from October 17, 2025, to October 16, 2030, for the quantitative measurement of glial fibrillary acidic protein concentration in human serum or plasma [2] - The blood cell analyzer calibration product has a registration number of 20252400180, valid from October 17, 2025, to October 16, 2030, for calibrating parameters such as WBC, RBC, HGB, HCT, and PLT in blood cell analysis [2]